Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date.

ABSTRACT: Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma characterized by an aggressive clinical course in the majority of patients. Despite recent improvements in outcomes, MCL remains incurable and a major therapeutic challenge. BTK inhibitors are the preferred treatment option for patients with relapsed/refractory MCL, including those unfit for chemotherapy or those with chemoresistant disease. In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of patients with relapsed/refractory MCL based on the results of two Phase 2 clinical trials showing overall response rates of 85-87% with complete responses in 30-77% of patients. Compared with ibrutinib, zanubrutinib is more selective for BTK and has less off-target inhibition, whic

SUBMITTER: Sawalha Y 

PROVIDER: S-EPMC7351990 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature